AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

Inflation can benefit payments companies generally because they take a small slice of every transaction. So in theory their take should rise along with the general price level. But if inflation is ...

The agency argues that reverse-payment agreements ... company paying compensation to the generic in exchange for the generic's agreement to stop contesting the patent and stay out of the market." ...

or a generic drug manufacturer from Feb. 1, 2018, until the class certification order. In exchange for the settlement payment, the plaintiff class will dismiss its legal action against Gilead and its ...

The plaintiffs allege the accord was an unlawful “reverse payment agreement" that delayed Hikma from marketing generic Xyrem for years. Hikma’s generic entered the market last year.

The new FDA-funded collaboration builds on research performed by EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under the first ...

Collegium Pharmaceutical (NASDAQ:COLL) Monday said that it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA, pursuant to which Hikma will have the exclusive right to ...